Ireland - English - HPRA (Health Products Regulatory Authority)

bausch health ireland limited - hypromellose - eye drops, solution - 3.2 milligram(s)/millilitre - other ophthalmologicals; artificial tears and other indifferent preparations

Ireland - English - HPRA (Health Products Regulatory Authority)

b & s healthcare - propranolol hydrochloride - prolonged release capsules - 160 milligram

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 0.8mg equivalent to 0.5 mg rivastigmine - capsule - 0.5 mg - active: rivastigmine tartrate 0.8mg equivalent to 0.5 mg rivastigmine excipient: colloidal silicon dioxide gelatin   hypromellose iron oxide red iron oxide yellow   magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv titanium dioxide  

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 2.4mg equivalent 1.5 mg rivastigmine;   - capsule - 1.5 mg - active: rivastigmine tartrate 2.4mg equivalent 1.5 mg rivastigmine   excipient: colloidal silicon dioxide gelatin hypromellose iron oxide yellow magnesium stearate microcrystalline cellulose tekprint red sw-1102 titanium dioxide - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 1.6mg equivalent to 1 mg rivastigmine - capsule - 1 mg - active: rivastigmine tartrate 1.6mg equivalent to 1 mg rivastigmine excipient: colloidal silicon dioxide gelatin   hypromellose iron oxide red iron oxide yellow   magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv titanium dioxide   - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 4.8mg equivalent 3 mg rivastigmine;   - capsule - 3 mg - active: rivastigmine tartrate 4.8mg equivalent 3 mg rivastigmine   excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose tekprint red sw-1102 titanium dioxide - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 7.2mg equivalent to 4.5 mg rivastigmine;   - capsule - 4.5 mg - active: rivastigmine tartrate 7.2mg equivalent to 4.5 mg rivastigmine   excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose opacode white s-1-18086 titanium dioxide - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 9.6mg equivalent to 6 mg rivastigmine;   - capsule - 6 mg - active: rivastigmine tartrate 9.6mg equivalent to 6 mg rivastigmine   excipient: colloidal silicon dioxide gelatin   hypromellose iron oxide red   iron oxide yellow   magnesium stearate microcrystalline cellulose tekprint red sw-1102 titanium dioxide   - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 3.2 mg/ml equivalent to 2 mg/ml rivastigmine base;   - oral solution - 2 mg/ml - active: rivastigmine tartrate 3.2 mg/ml equivalent to 2 mg/ml rivastigmine base   excipient: citric acid monohydrate purified water quinoline yellow sodium benzoate sodium citrate dihydrate - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.

Ireland - English - HPRA (Health Products Regulatory Authority)

bausch & lomb uk limited - hypromellose - eye drops solution - 3.2 mg/ml - artificial tears and other indifferent preparations